Exact Mass: 357.21262360000003

Exact Mass Matches: 357.21262360000003

Found 346 metabolites which its exact mass value is equals to given mass value 357.21262360000003, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Zongorine

(1R,2R,5S,7R,8R,9R,13R,16S,17R)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecan-4-one

C22H31NO3 (357.2303816)


Songorine is a kaurane diterpenoid. Songorine is a diterpenoid alkaloid isolated from the genus Aconitum. Songorine is a GABAA receptor antagonist in rat brain and has anti cancer, antiarrhythmic and anti-inflammatory activities. Songorine has the potential for the treatment of Epithelial ovarian cancer (EOC)[1]. Songorine is a diterpenoid alkaloid isolated from the genus Aconitum. Songorine is a GABAA receptor antagonist in rat brain and has anti cancer, antiarrhythmic and anti-inflammatory activities. Songorine has the potential for the treatment of Epithelial ovarian cancer (EOC)[1]. Songorine is a diterpenoid alkaloid isolated from the genus Aconitum. Songorine is a GABAA receptor antagonist in rat brain and has anti cancer, antiarrhythmic and anti-inflammatory activities. Songorine has the potential for the treatment of Epithelial ovarian cancer (EOC)[1].

   

Oxybutynin

Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester

C22H31NO3 (357.2303816)


Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor. G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D000890 - Anti-Infective Agents > D000892 - Anti-Infective Agents, Urinary > D008333 - Mandelic Acids D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3025 Oxybutynin is an anticholinergic agent, which inhibits vascular Kv channels in a concentration-dependent manner, with an IC50 of 11.51 μM[1]. Oxybutynin is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

   

(S)-Laudanosine

1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline

C21H27NO4 (357.19399820000007)


(S)-Laudanosine is found in opium poppy. (S)-Laudanosine is an alkaloid from Papaver somniferum (opium poppy Alkaloid from Papaver somniferum (opium poppy). (S)-Laudanosine is found in opium poppy. D002491 - Central Nervous System Agents DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1]. DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1].

   

Nalbuphine

(1S,5R,13R,14S,17S)-4-(cyclobutylmethyl)-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-triene-10,14,17-triol

C21H27NO4 (357.19399820000007)


Nalbuphine is only found in individuals that have used or taken this drug. It is a narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. [PubChem]The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Nalbuphine is thought primarily to be a kappa agonist. It is also a partial mu antagonist analgesic, with some binding to the delta receptor and minimal agonist activity at the sigma receptor. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AF - Morphinan derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Proteinase inhibitor E 64

3-[[[(1S)-1-[[[4-[(aminoiminomethyl)amino]butyl]amino]carbonyl]-3-methylbutyl]amino]carbonyl]-(2S,3S)-oxiranecarboxylic acid

C15H27N5O5 (357.2012092)


D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents KEIO_ID E015; [MS2] KO008950 KEIO_ID E015

   

Uplandicine

Uplandicine; 7-Acetyl-9-echimidinylretronecine

C17H27NO7 (357.1787432)


   

N-Desmethyltamoxifen

(2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)(methyl)amine

C25H27NO (357.20925320000003)


N-Desmethyltamoxifen is only found in individuals that have used or taken Tamoxifen. N-Desmethyltamoxifen is a metabolite of Tamoxifen. N-desmethyltamoxifen belongs to the family of Stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent

   

Cinacalcet

alpha-Methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethanamine, (alphar)-hydrochloride

C22H22F3N (357.17042480000003)


Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe. Cinacalcet is used to treat hyperparathyroidism (elevated parathyroid hormone levels), a consequence of parathyroid tumors and chronic renal failure. D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D057966 - Calcimimetic Agents H - Systemic hormonal preparations, excl. sex hormones and insulins > H05 - Calcium homeostasis > H05B - Anti-parathyroid agents C78275 - Agent Affecting Blood or Body Fluid > C2136 - Malignancy-Associated Hypercalcemia Inhibitor D000077264 - Calcium-Regulating Hormones and Agents

   

Dihydroretrofractamide B

(2E,4E)-11-(2H-1,3-Benzodioxol-5-yl)-N-(2-methylpropyl)undeca-2,4-dienimidate

C22H31NO3 (357.2303816)


Dihydroretrofractamide B is found in herbs and spices. Dihydroretrofractamide B is an alkaloid from the fruit of Piper nigrum (pepper). Alkaloid from the fruit of Piper nigrum (pepper). Dihydroretrofractamide B is found in herbs and spices and pepper (spice).

   

5-hydroxypropafenone

1-{5-hydroxy-2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one

C21H27NO4 (357.19399820000007)


5-hydroxypropafenone is a metabolite of propafenone. Propafenone is a class of anti-arrhythmic medication, which treats illnesses associated with rapid heart beats such as atrial and ventricular arrhythmias. (Wikipedia) D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents

   

(9Z)-3-Hydroxydodecenoylcarnitine

3-{[(9Z)-3-hydroxydodec-9-enoyl]oxy}-4-(trimethylammonio)butanoic acid

C19H35NO5 (357.25151000000005)


(9Z)-3-Hydroxydodecenoylcarnitine is an acylcarnitine. More specifically, it is an (9Z)-hydroxydodec-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z)-3-Hydroxydodecenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (9Z)-3-Hydroxydodecenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Undec-5-enedioylcarnitine

3-[(10-carboxydec-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H31NO6 (357.2151266)


Undec-5-enedioylcarnitine is an acylcarnitine. More specifically, it is an undec-5-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undec-5-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undec-5-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E)-Undec-2-enedioylcarnitine

3-[(10-carboxydec-2-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H31NO6 (357.2151266)


(2E)-Undec-2-enedioylcarnitine is an acylcarnitine. More specifically, it is an (2E)-undec-2-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E)-Undec-2-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E)-Undec-2-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Undec-4-enedioylcarnitine

3-[(10-carboxydec-7-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H31NO6 (357.2151266)


Undec-4-enedioylcarnitine is an acylcarnitine. More specifically, it is an undec-4-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undec-4-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undec-4-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Undec-3-enedioylcarnitine

3-[(10-carboxydec-8-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H31NO6 (357.2151266)


Undec-3-enedioylcarnitine is an acylcarnitine. More specifically, it is an undec-3-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undec-3-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undec-3-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4E)-3-Hydroxydodec-4-enoylcarnitine

3-[(3-hydroxydodec-4-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H35NO5 (357.25151000000005)


(4E)-3-Hydroxydodec-4-enoylcarnitine is an acylcarnitine. More specifically, it is an (4E)-3-hydroxydodec-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E)-3-Hydroxydodec-4-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E)-3-Hydroxydodec-4-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6Z)-3-Hydroxydodec-6-enoylcarnitine

3-[(3-hydroxydodec-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H35NO5 (357.25151000000005)


(6Z)-3-Hydroxydodec-6-enoylcarnitine is an acylcarnitine. More specifically, it is an (6Z)-3-hydroxydodec-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z)-3-Hydroxydodec-6-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (6Z)-3-Hydroxydodec-6-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(8Z)-3-Hydroxydodec-8-enoylcarnitine

3-[(3-hydroxydodec-8-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H35NO5 (357.25151000000005)


(8Z)-3-Hydroxydodec-8-enoylcarnitine is an acylcarnitine. More specifically, it is an (8Z)-3-hydroxydodec-8-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8Z)-3-Hydroxydodec-8-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (8Z)-3-Hydroxydodec-8-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(7E)-5-Hydroxydodec-7-enoylcarnitine

3-[(5-hydroxydodec-7-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H35NO5 (357.25151000000005)


(7E)-5-Hydroxydodec-7-enoylcarnitine is an acylcarnitine. More specifically, it is an (7E)-5-hydroxydodec-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7E)-5-Hydroxydodec-7-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (7E)-5-Hydroxydodec-7-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(9E)-7-Hydroxydodec-9-enoylcarnitine

3-[(7-hydroxydodec-9-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H35NO5 (357.25151000000005)


(9E)-7-Hydroxydodec-9-enoylcarnitine is an acylcarnitine. More specifically, it is an (9E)-7-hydroxydodec-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9E)-7-Hydroxydodec-9-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (9E)-7-Hydroxydodec-9-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(10E)-8-Hydroxydodec-10-enoylcarnitine

3-[(8-hydroxydodec-10-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H35NO5 (357.25151000000005)


(10E)-8-Hydroxydodec-10-enoylcarnitine is an acylcarnitine. More specifically, it is an (10E)-8-hydroxydodec-10-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (10E)-8-Hydroxydodec-10-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (10E)-8-Hydroxydodec-10-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-oxododecanoylcarnitine

3-[(3-oxododecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H35NO5 (357.25151000000005)


3-oxododecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-oxododecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-oxododecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-oxododecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Myristoyl Glutamic acid

2-[(1-Hydroxytetradecylidene)amino]pentanedioate

C19H35NO5 (357.25151000000005)


N-myristoyl glutamic acid, also known as N-myristoyl glutamate belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Myristic acid amide of Glutamic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Myristoyl Glutamic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Myristoyl Glutamic acid is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

4,17-Dimethyltrilostane

15-hydroxy-2,6,15,16-tetramethyl-5-oxo-7-oxapentacyclo[9.7.0.0^{2,8}.0^{6,8}.0^{12,16}]octadecane-4-carbonitrile

C22H31NO3 (357.2303816)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones

   

N-(8-Amino-1-carboxyoctyl)-alanyl-proline

1-{2-[(8-amino-1-carboxyoctyl)amino]propanoyl}pyrrolidine-2-carboxylic acid

C17H31N3O5 (357.2263596)


   

(3R,5R)-3-Butyl-3-ethyl-5-phenyl-4,5-dihydro-2H-1$l^{6},4-benzothiazepine 1,1-dioxide

(3R,5R)-3-Butyl-3-ethyl-5-phenyl-4,5-dihydro-2H-1$l^{6},4-benzothiazepine 1,1-dioxide

C21H27NO2S (357.17624020000005)


   

Quinocarmycin analog

12-cyano-10-(hydroxymethyl)-8-methoxy-16-methyl-11,16-diazatetracyclo[11.2.1.0^{2,11}.0^{4,9}]hexadeca-4(9),5,7-triene-15-carboxylic acid

C19H23N3O4 (357.16884780000004)


D000970 - Antineoplastic Agents

   

(2R,3R)-3-[[(2S)-1-[4-(Diaminomethylideneamino)butylamino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid

(2R,3R)-3-[[(2S)-1-[4-(Diaminomethylideneamino)butylamino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid

C15H27N5O5 (357.2012092)


   

Enecadin

4-(4-Fluorophenyl)-2-methyl-6-(5-piperidinopentyloxy)pyrimidine hydrochloride

C21H28FN3O (357.221629)


C26170 - Protective Agent > C1509 - Neuroprotective Agent

   

Epostane

5,15-dihydroxy-2,6,15,16-tetramethyl-7-oxapentacyclo[9.7.0.0^{2,8}.0^{6,8}.0^{12,16}]octadec-4-ene-4-carbonitrile

C22H31NO3 (357.2303816)


   

Phencynonate

3-Methyl-3-azabicyclo[3.3.1]nonan-9-yl 2-cyclopentyl-2-hydroxy-2-phenylacetic acid

C22H31NO3 (357.2303816)


   

Piperchabamide D

(2E,10E)-11-(2H-1,3-Benzodioxol-5-yl)-N-(butan-2-yl)undeca-2,10-dienimidate

C22H31NO3 (357.2303816)


Piperchabamide d is practically insoluble (in water) and an extremely weak acidic compound (based on its pKa). Piperchabamide d can be found in pepper (spice), which makes piperchabamide d a potential biomarker for the consumption of this food product.

   

delta-9-tetrahydrocannabinolate

1-Hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene-2-carboxylic acid

C22H29O4 (357.2065734)


delta9-tetrahydrocannabinolate is also known as thca or δ9-tetrahydrocannabinolic acid. delta9-tetrahydrocannabinolate is practically insoluble (in water) and a moderately acidic compound (based on its pKa). delta9-tetrahydrocannabinolate can be found in a number of food items such as devilfish, arrowhead, potato, and cereals and cereal products, which makes delta9-tetrahydrocannabinolate a potential biomarker for the consumption of these food products.

   
   

(E)-(4-Acetoxycinnamoyl)-epilupinine

(E)-(4-Acetoxycinnamoyl)-epilupinine

C21H27NO4 (357.19399820000007)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

Yuzurimic acid B

(+)-Yuzurimic acid B

C22H31NO3 (357.2303816)


   
   

12-epi-Dehydronapelline

(+)-12-Epidehydronapelline

C22H31NO3 (357.2303816)


   

JWH 018 4-hydroxyindole metabolite

(4-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)-methanone

C24H23NO2 (357.1728698)


   
   

JWH 018 5-hydroxyindole metabolite

(5-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)-methanone

C24H23NO2 (357.1728698)


   

(6-hydroxy-1-pentylindol-3-yl)-naphthalen-1-ylmethanone

(6-hydroxy-1-pentylindol-3-yl)-naphthalen-1-ylmethanone

C24H23NO2 (357.1728698)


   

JWH 018 7-hydroxyindole metabolite

(7-hydroxy-1-pentyl-1H-indol-3-yl)naphthalen-1-yl)-methanone

C24H23NO2 (357.1728698)


   
   
   

JWH 018 8-quinolinyl carboxamide

JWH 018 8-quinolinyl carboxamide

C23H23N3O (357.1841028)


   
   

N-(naphthalen-1-yl)-2-pentyl-2h-indazole-3-carboxamide

N-(naphthalen-1-yl)-2-pentyl-2h-indazole-3-carboxamide

C23H23N3O (357.1841028)


   

(1-butylindol-3-yl)-(4-methoxynaphthalen-1-yl)methanone

(1-butylindol-3-yl)-(4-methoxynaphthalen-1-yl)methanone

C24H23NO2 (357.1728698)


   
   
   

Oroboidin|pyrrole-3-carboxylic acid 13-oxo-dodecahydro-7,14-methano-dipyrido[1,2-a;1,2-e][1,5]diazocin-2-yl ester

Oroboidin|pyrrole-3-carboxylic acid 13-oxo-dodecahydro-7,14-methano-dipyrido[1,2-a;1,2-e][1,5]diazocin-2-yl ester

C20H27N3O3 (357.20523120000007)


   

songorine hydrochloride

songorine hydrochloride

C22H31NO3 (357.2303816)


   
   

(2S)-[(2S)-aminopropionylamino]-5-{[(3S)-((1S)-methylpropyl)-4-oxooxetane-(2R)-carbonyl]amino}pentanoic acid|belactosin C

(2S)-[(2S)-aminopropionylamino]-5-{[(3S)-((1S)-methylpropyl)-4-oxooxetane-(2R)-carbonyl]amino}pentanoic acid|belactosin C

C16H27N3O6 (357.1899762)


   
   
   
   

methyl 4-((E)-2-acetyl-4-oxonon-1-enyl)-6-((E)-prop-1-enyl)nicotinate|monascopyridine E|Monasnicotinate A

methyl 4-((E)-2-acetyl-4-oxonon-1-enyl)-6-((E)-prop-1-enyl)nicotinate|monascopyridine E|Monasnicotinate A

C21H27NO4 (357.19399820000007)


   
   
   
   
   
   
   
   
   
   
   
   

asparagylprolyllysine

asparagylprolyllysine

C15H27N5O5 (357.2012092)


   
   
   
   
   
   
   
   
   
   

3-Acetylindicine N-oxide

3-Acetylindicine N-oxide

C17H27NO7 (357.1787432)


   
   

Laudanosine

DL-LAUDANOSINE

C21H27NO4 (357.19399820000007)


D002491 - Central Nervous System Agents Annotation level-1 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.628 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.624 Acquisition and generation of the data is financially supported by the Max-Planck-Society IPB_RECORD: 2441; CONFIDENCE confident structure DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1]. DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1].

   
   

Oxybutynin

Oxybutynin (Ditropan)

C22H31NO3 (357.2303816)


G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D000890 - Anti-Infective Agents > D000892 - Anti-Infective Agents, Urinary > D008333 - Mandelic Acids D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents CONFIDENCE standard compound; INTERNAL_ID 2516 CONFIDENCE standard compound; INTERNAL_ID 8497 Oxybutynin is an anticholinergic agent, which inhibits vascular Kv channels in a concentration-dependent manner, with an IC50 of 11.51 μM[1]. Oxybutynin is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

   

C19H23N3O4_2H-Pyrazino[1,2:1,5]pyrrolo[2,3-b]indole-1,4(3H,5aH)-dione, 6-acetyl-6,10b,11,11a-tetrahydro-10b-hydroxy-3-(2-methylpropyl)

NCGC00380403-01_C19H23N3O4_2H-Pyrazino[1,2:1,5]pyrrolo[2,3-b]indole-1,4(3H,5aH)-dione, 6-acetyl-6,10b,11,11a-tetrahydro-10b-hydroxy-3-(2-methylpropyl)-

C19H23N3O4 (357.16884780000004)


   

nalbuphine

nalbuphine

C21H27NO4 (357.19399820000007)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AF - Morphinan derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

5-hydroxypropafenone

5-hydroxypropafenone

C21H27NO4 (357.19399820000007)


D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents

   

Laudanoside

Laudanoside

C21H27NO4 (357.19399820000007)


Origin: Plant; Formula(Parent): C21H27NO4; Bottle Name:Laudanosine; PRIME Parent Name:Laudanosine; PRIME in-house No.:V0357; SubCategory_DNP: Isoquinoline alkaloids, Morphine alkaloids

   

songorine

(1R,2R,5R,7R,8S,13R,16S,17R)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecan-4-one

C22H31NO3 (357.2303816)


Origin: Plant; SubCategory_DNP: Terpenoid alkaloids, Diterpene alkaloid, Aconitum alkaloid Songorine is a diterpenoid alkaloid isolated from the genus Aconitum. Songorine is a GABAA receptor antagonist in rat brain and has anti cancer, antiarrhythmic and anti-inflammatory activities. Songorine has the potential for the treatment of Epithelial ovarian cancer (EOC)[1]. Songorine is a diterpenoid alkaloid isolated from the genus Aconitum. Songorine is a GABAA receptor antagonist in rat brain and has anti cancer, antiarrhythmic and anti-inflammatory activities. Songorine has the potential for the treatment of Epithelial ovarian cancer (EOC)[1]. Songorine is a diterpenoid alkaloid isolated from the genus Aconitum. Songorine is a GABAA receptor antagonist in rat brain and has anti cancer, antiarrhythmic and anti-inflammatory activities. Songorine has the potential for the treatment of Epithelial ovarian cancer (EOC)[1].

   

Ala Gly Asn Pro

(2S)-1-[(2S)-2-{2-[(2S)-2-aminopropanamido]acetamido}-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

C14H23N5O6 (357.1648258)


   

Ala Gly Pro Asn

(2S)-2-{[(2S)-1-{2-[(2S)-2-aminopropanamido]acetyl}pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

C14H23N5O6 (357.1648258)


   

Ala Asn Gly Pro

(2S)-1-{2-[(2S)-2-[(2S)-2-aminopropanamido]-3-carbamoylpropanamido]acetyl}pyrrolidine-2-carboxylic acid

C14H23N5O6 (357.1648258)


   

Ala Asn Pro Gly

2-{[(2S)-1-[(2S)-2-[(2S)-2-aminopropanamido]-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}acetic acid

C14H23N5O6 (357.1648258)


   

Ala Pro Gly Asn

(2S)-2-(2-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}acetamido)-3-carbamoylpropanoic acid

C14H23N5O6 (357.1648258)


   

Ala Pro Asn Gly

2-[(2S)-2-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanamido]acetic acid

C14H23N5O6 (357.1648258)


   

Gly Ala Asn Pro

(2S)-1-[(2S)-2-[(2S)-2-(2-aminoacetamido)propanamido]-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

C14H23N5O6 (357.1648258)


   

Gly Ala Pro Asn

(2S)-2-{[(2S)-1-[(2S)-2-(2-aminoacetamido)propanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

C14H23N5O6 (357.1648258)


   

Gly Gly Lys Pro

(2S)-1-[(2S)-6-amino-2-[2-(2-aminoacetamido)acetamido]hexanoyl]pyrrolidine-2-carboxylic acid

C15H27N5O5 (357.2012092)


   

Gly Gly Pro Lys

(2S)-6-amino-2-{[(2S)-1-[2-(2-aminoacetamido)acetyl]pyrrolidin-2-yl]formamido}hexanoic acid

C15H27N5O5 (357.2012092)


   

Gly Gly Pro Gln

(2S)-2-{[(2S)-1-[2-(2-aminoacetamido)acetyl]pyrrolidin-2-yl]formamido}-4-carbamoylbutanoic acid

C14H23N5O6 (357.1648258)


   

Gly Gly Gln Pro

(2S)-1-[(2S)-2-[2-(2-aminoacetamido)acetamido]-4-carbamoylbutanoyl]pyrrolidine-2-carboxylic acid

C14H23N5O6 (357.1648258)


   

Gly Lys Gly Pro

(2S)-1-{2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]acetyl}pyrrolidine-2-carboxylic acid

C15H27N5O5 (357.2012092)


   

Gly Lys Pro Gly

2-{[(2S)-1-[(2S)-6-amino-2-(2-aminoacetamido)hexanoyl]pyrrolidin-2-yl]formamido}acetic acid

C15H27N5O5 (357.2012092)


   

Gly Asn Ala Pro

(2S)-1-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]propanoyl]pyrrolidine-2-carboxylic acid

C14H23N5O6 (357.1648258)


   

Gly Asn Pro Ala

(2S)-2-{[(2S)-1-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}propanoic acid

C14H23N5O6 (357.1648258)


   

Gly Pro Ala Asn

(2S)-2-[(2S)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}propanamido]-3-carbamoylpropanoic acid

C14H23N5O6 (357.1648258)


   

Gly Pro Gly Lys

(2S)-6-amino-2-(2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}acetamido)hexanoic acid

C15H27N5O5 (357.2012092)


   

Gly Pro Gly Gln

(2S)-2-(2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}acetamido)-4-carbamoylbutanoic acid

C14H23N5O6 (357.1648258)


   

Gly Pro Lys Gly

2-[(2S)-6-amino-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}hexanamido]acetic acid

C15H27N5O5 (357.2012092)


   

Gly Pro Asn Ala

(2S)-2-[(2S)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}-3-carbamoylpropanamido]propanoic acid

C14H23N5O6 (357.1648258)


   

Gly Pro Gln Gly

2-[(2S)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}-4-carbamoylbutanamido]acetic acid

C14H23N5O6 (357.1648258)


   

Gly Gln Gly Pro

(2S)-1-{2-[(2S)-2-(2-aminoacetamido)-4-carbamoylbutanamido]acetyl}pyrrolidine-2-carboxylic acid

C14H23N5O6 (357.1648258)


   

Gly Gln Pro Gly

2-{[(2S)-1-[(2S)-2-(2-aminoacetamido)-4-carbamoylbutanoyl]pyrrolidin-2-yl]formamido}acetic acid

C14H23N5O6 (357.1648258)


   
   
   
   

Lys Gly Gly Pro

(2S)-1-(2-{2-[(2S)-2,6-diaminohexanamido]acetamido}acetyl)pyrrolidine-2-carboxylic acid

C15H27N5O5 (357.2012092)


   

Lys Gly Pro Gly

2-{[(2S)-1-{2-[(2S)-2,6-diaminohexanamido]acetyl}pyrrolidin-2-yl]formamido}acetic acid

C15H27N5O5 (357.2012092)


   

Lys Pro Gly Gly

2-(2-{[(2S)-1-[(2S)-2,6-diaminohexanoyl]pyrrolidin-2-yl]formamido}acetamido)acetic acid

C15H27N5O5 (357.2012092)


   
   
   
   
   

Asn Ala Gly Pro

(2S)-1-{2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]propanamido]acetyl}pyrrolidine-2-carboxylic acid

C14H23N5O6 (357.1648258)


   

Asn Ala Pro Gly

2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]propanoyl]pyrrolidin-2-yl]formamido}acetic acid

C14H23N5O6 (357.1648258)


   

Asn Gly Ala Pro

(2S)-1-[(2S)-2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}propanoyl]pyrrolidine-2-carboxylic acid

C14H23N5O6 (357.1648258)


   

Asn Gly Pro Ala

(2S)-2-{[(2S)-1-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetyl}pyrrolidin-2-yl]formamido}propanoic acid

C14H23N5O6 (357.1648258)


   

Asn Pro Ala Gly

2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}propanamido]acetic acid

C14H23N5O6 (357.1648258)


   

Asn Pro Gly Ala

(2S)-2-(2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}acetamido)propanoic acid

C14H23N5O6 (357.1648258)


   
   

Pro Ala Gly Asn

(2S)-3-carbamoyl-2-{2-[(2S)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]acetamido}propanoic acid

C14H23N5O6 (357.1648258)


   

Pro Ala Asn Gly

2-[(2S)-3-carbamoyl-2-[(2S)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]propanamido]acetic acid

C14H23N5O6 (357.1648258)


   
   

Pro Gly Ala Asn

(2S)-3-carbamoyl-2-[(2S)-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}propanamido]propanoic acid

C14H23N5O6 (357.1648258)


   

Pro Gly Gly Lys

(2S)-6-amino-2-(2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}acetamido)hexanoic acid

C15H27N5O5 (357.2012092)


   

Pro Gly Gly Gln

(2S)-4-carbamoyl-2-(2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}acetamido)butanoic acid

C14H23N5O6 (357.1648258)


   

Pro Gly Lys Gly

2-[(2S)-6-amino-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}hexanamido]acetic acid

C15H27N5O5 (357.2012092)


   

Pro Gly Asn Ala

(2S)-2-[(2S)-3-carbamoyl-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}propanamido]propanoic acid

C14H23N5O6 (357.1648258)


   

Pro Gly Gln Gly

2-[(2S)-4-carbamoyl-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}butanamido]acetic acid

C14H23N5O6 (357.1648258)


   
   

Pro Lys Gly Gly

2-{2-[(2S)-6-amino-2-[(2S)-pyrrolidin-2-ylformamido]hexanamido]acetamido}acetic acid

C15H27N5O5 (357.2012092)


   

Pro Asn Ala Gly

2-[(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]propanamido]acetic acid

C14H23N5O6 (357.1648258)


   

Pro Asn Gly Ala

(2S)-2-{2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]acetamido}propanoic acid

C14H23N5O6 (357.1648258)


   

Pro Gln Gly Gly

2-{2-[(2S)-4-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]acetamido}acetic acid

C14H23N5O6 (357.1648258)


   

Gln Gly Gly Pro

(2S)-1-(2-{2-[(2S)-2-amino-4-carbamoylbutanamido]acetamido}acetyl)pyrrolidine-2-carboxylic acid

C14H23N5O6 (357.1648258)


   

Gln Gly Pro Gly

2-{[(2S)-1-{2-[(2S)-2-amino-4-carbamoylbutanamido]acetyl}pyrrolidin-2-yl]formamido}acetic acid

C14H23N5O6 (357.1648258)


   

Gln Pro Gly Gly

2-(2-{[(2S)-1-[(2S)-2-amino-4-carbamoylbutanoyl]pyrrolidin-2-yl]formamido}acetamido)acetic acid

C14H23N5O6 (357.1648258)


   
   
   
   
   
   
   

Farnesyl Thiosalicylic Acid Amide

Farnesyl Thiosalicylic Acid Amide

C22H31NOS (357.21262360000003)


   

JWH 018 2-hydroxyindole metabolite

(2-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)-methanone

C24H23NO2 (357.1728698)


   

JWH 018 6-hydroxyindole metabolite

(6-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)-methanone

C24H23NO2 (357.1728698)


   

JWH 018 N-(5-hydroxypentyl) metabolite

(1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)-methanone

C24H23NO2 (357.1728698)


   

Cinacalcet

[(1R)-1-(naphthalen-1-yl)ethyl]({3-[3-(trifluoromethyl)phenyl]propyl})amine

C22H22F3N (357.17042480000003)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D057966 - Calcimimetic Agents H - Systemic hormonal preparations, excl. sex hormones and insulins > H05 - Calcium homeostasis > H05B - Anti-parathyroid agents C78275 - Agent Affecting Blood or Body Fluid > C2136 - Malignancy-Associated Hypercalcemia Inhibitor D000077264 - Calcium-Regulating Hormones and Agents

   

Dihydroretrofractamide B

(2E,4E)-11-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)undeca-2,4-dienamide

C22H31NO3 (357.2303816)


   

5(S),6(R)-Lipoxin A4-d5

5(S),6(R)-Lipoxin A4-d5

C20H27D5O5 (357.25634809)


   

(S)-(+)-JWH 018 N-(4-hydroxypentyl) metabolite

(S)-(+)-JWH 018 N-(4-hydroxypentyl) metabolite

C24H23NO2 (357.1728698)


   

(±)-JWH 018 N-(3-hydroxypentyl) metabolite

(±)-JWH 018 N-(3-hydroxypentyl) metabolite

C24H23NO2 (357.1728698)


   

(±)-JWH 018 N-(2-hydroxypentyl) metabolite

(±)-JWH 018 N-(2-hydroxypentyl) metabolite

C24H23NO2 (357.1728698)


   

6-Acetyl-10b-hydroxy-3-isobutyl-6,10b,11,11a-tetrahydro-2H-pyrazino[1,2:1,5]pyrrolo[2,3-b]indole-1,4(3H,5aH)-dione

6-Acetyl-10b-hydroxy-3-isobutyl-6,10b,11,11a-tetrahydro-2H-pyrazino[1,2:1,5]pyrrolo[2,3-b]indole-1,4(3H,5aH)-dione

C19H23N3O4 (357.16884780000004)


   

CAR 12:1;O

3-{[(9Z)-3-hydroxydodec-9-enoyl]oxy}-4-(trimethylammonio)butanoate;cis-3-hydroxydodec-9-enoylcarnitine

C19H35NO5 (357.25151000000005)


   

Bacillamidin B

(1?R)-10-methyldodecanoyl dimethylaspartate

C19H35NO5 (357.25151000000005)


   
   

butyl prop-2-enoate,prop-2-enenitrile,prop-2-enoic acid,styrene

butyl prop-2-enoate,prop-2-enenitrile,prop-2-enoic acid,styrene

C21H27NO4 (357.19399820000007)


   

4-ISOTHIOCYANATOPHENYL 4-PENTYLBICYCLO

4-ISOTHIOCYANATOPHENYL 4-PENTYLBICYCLO

C21H27NO2S (357.17624020000005)


   
   

(S)-(+)-3-METHYL-2-BUTYLAMINE

(S)-(+)-3-METHYL-2-BUTYLAMINE

C24H23NO2 (357.1728698)


   

2-((tert-butyldiphenylsilyl)oxy)-N-methoxy-N-methylacetamide

2-((tert-butyldiphenylsilyl)oxy)-N-methoxy-N-methylacetamide

C20H27NO3Si (357.1760112)


   

Cafedrine

(-)-Cafedrine

C18H23N5O3 (357.18008080000004)


C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

   

6-(4-Cyclopentylpiperazin-1-yl)pyridine-3-boronic acid pinacol ester

6-(4-Cyclopentylpiperazin-1-yl)pyridine-3-boronic acid pinacol ester

C20H32BN3O2 (357.25874419999997)


   

Setastine

1-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]azepane

C22H28ClNO (357.18593080000005)


C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist

   

4,7-dimethyl-5,6-bis(phenylmethoxy)-1H-indole

4,7-dimethyl-5,6-bis(phenylmethoxy)-1H-indole

C24H23NO2 (357.1728698)


   

N,N-dibenzyl-1-(phenylmethoxymethyl)cyclopropan-1-amine

N,N-dibenzyl-1-(phenylmethoxymethyl)cyclopropan-1-amine

C25H27NO (357.20925320000003)


   

sodium 1-(carboxymethyl)-4,5-dihydro-1-(2-hydroxyethyl)-2-nonyl-1H-imidazolium hydroxide

sodium 1-(carboxymethyl)-4,5-dihydro-1-(2-hydroxyethyl)-2-nonyl-1H-imidazolium hydroxide

C16H34N2NaO5+ (357.2365294)


   

Esoxybutynin

Esoxybutynin

C22H31NO3 (357.2303816)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent

   

tert-Butyl 6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate

tert-Butyl 6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate

C20H28BNO4 (357.21112780000004)


   

tert-Butyl 6-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate

tert-Butyl 6-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate

C20H28BNO4 (357.21112780000004)


   

tert-Butyl 7-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate

tert-Butyl 7-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate

C20H28BNO4 (357.21112780000004)


   

(R)-1,1,2-TRIPHENYL-2-(PIPERIDIN-1-YL)ETHANOL

(R)-1,1,2-TRIPHENYL-2-(PIPERIDIN-1-YL)ETHANOL

C25H27NO (357.20925320000003)


   

(R)-(-)-5-(TRITYLOXYMETHYL)-2-PYRROLIDONE

(R)-(-)-5-(TRITYLOXYMETHYL)-2-PYRROLIDONE

C24H23NO2 (357.1728698)


   

4-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)phenyl]morpholine

4-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)phenyl]morpholine

C17H23BF3NO3 (357.17229940000004)


   

dodecyl-(2-hydroxyethyl)-dimethylazanium,perchlorate

dodecyl-(2-hydroxyethyl)-dimethylazanium,perchlorate

C16H36ClNO5 (357.22818760000007)


   

(S)-1,1,2-TRIPHENYL-2-(PIPERIDIN-1-YL)ETHANOL

(S)-1,1,2-TRIPHENYL-2-(PIPERIDIN-1-YL)ETHANOL

C25H27NO (357.20925320000003)


   
   

1-(TERT-BUTYLDIMETHYLSILYL)-3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1H-INDOLE

1-(TERT-BUTYLDIMETHYLSILYL)-3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1H-INDOLE

C20H32BNO2Si (357.22952419999996)


   
   
   

2-({6-[(3R)-3-Amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)benzamide

2-({6-[(3R)-3-Amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)benzamide

C18H23N5O3 (357.18008080000004)


   
   
   

(R)-N-(1-(naphthalen-1-yl)ethyl)-3-(4-(trifluoroMethyl)phenyl)propan-1-aMine

(R)-N-(1-(naphthalen-1-yl)ethyl)-3-(4-(trifluoroMethyl)phenyl)propan-1-aMine

C22H22F3N (357.17042480000003)


   
   

N-Biotinyl-6-aminohexanoic acid

6-[5-(2-Oxo-hexahydro-thieno[3,4-D]imidazol-4-YL)-pentanoylamino]-hexanoic acid

C16H27N3O4S (357.17221820000003)


   

1,3,5-tribenzyl-1,3,5-triazinane

1,3,5-tribenzyl-1,3,5-triazinane

C24H27N3 (357.22048620000004)


   

9-[3-(CIS-3,5-DIMETHYL-1-PIPERAZINYL)PROPYL]CARBAZOLE MONOHYDROCHLORIDE

9-[3-(CIS-3,5-DIMETHYL-1-PIPERAZINYL)PROPYL]CARBAZOLE MONOHYDROCHLORIDE

C21H28ClN3 (357.19716380000006)


   

Olorinab

Olorinab

C18H23N5O3 (357.18008080000004)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic

   

(2S,3R)-N-(2-(3-Pyridinylmethyl)-1-azabicyclo(2.2.2)oct-3-yl)-3,5-difluorobenzamide

(2S,3R)-N-(2-(3-Pyridinylmethyl)-1-azabicyclo(2.2.2)oct-3-yl)-3,5-difluorobenzamide

C20H21F2N3O (357.16526)


   

alpha-Bencynonatine

alpha-Bencynonatine

C22H31NO3 (357.2303816)


   

(R)-laudanosine

(R)-laudanosine

C21H27NO4 (357.19399820000007)


A benzylisoquinoline alkaloid that is (R)-tetrahydropapaverine in which the amino hydrogen has been replaced by a methyl group

   

(r)-Oxybutynin

(r)-Oxybutynin

C22H31NO3 (357.2303816)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent

   

4-(2-Pyridyl)piperazinyl 3,4,5-trimethoxyphenyl ketone

4-(2-Pyridyl)piperazinyl 3,4,5-trimethoxyphenyl ketone

C19H23N3O4 (357.16884780000004)


   

delta-9-tetrahydrocannabinolate

1-Hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene-2-carboxylic acid

C22H29O4 (357.2065734)


delta9-tetrahydrocannabinolate is also known as thca or δ9-tetrahydrocannabinolic acid. delta9-tetrahydrocannabinolate is practically insoluble (in water) and a moderately acidic compound (based on its pKa). delta9-tetrahydrocannabinolate can be found in a number of food items such as devilfish, arrowhead, potato, and cereals and cereal products, which makes delta9-tetrahydrocannabinolate a potential biomarker for the consumption of these food products. Δ9-tetrahydrocannabinolate is also known as thca or δ9-tetrahydrocannabinolic acid. Δ9-tetrahydrocannabinolate is practically insoluble (in water) and a moderately acidic compound (based on its pKa). Δ9-tetrahydrocannabinolate can be found in a number of food items such as devilfish, arrowhead, potato, and cereals and cereal products, which makes Δ9-tetrahydrocannabinolate a potential biomarker for the consumption of these food products.

   

Cannabichromenate

Cannabichromenate

C22H29O4- (357.2065734)


A hydroxy monocarboxylic acid anion that is the conjugate base of cannabichromenic acid, obtained by deprotonation of the carboxy group. Major species at pH 7.3.

   

Cannabidiolate

Cannabidiolate

C22H29O4- (357.2065734)


A dihydroxybenzoate that is the conjugate base of cannabidiolic acid, obtained by deprotonation of the carboxy group.

   
   

Delta(9)-tetrahydrocannabinolate

Delta(9)-tetrahydrocannabinolate

C22H29O4- (357.2065734)


A hydroxy monocarboxylic acid anion that is the conjugate base of Delta(9)-tetrahydrocannabinolic acid, obtained by deprotonation of the carboxy group.

   

(4Z)-6-{3-[(1E,3E,5Z,7E,9S,11Z)-9-hydroxytetradeca-1,3,5,7,11-pentaen-1-yl]oxiran-2-yl}hex-4-enoate

(4Z)-6-{3-[(1E,3E,5Z,7E,9S,11Z)-9-hydroxytetradeca-1,3,5,7,11-pentaen-1-yl]oxiran-2-yl}hex-4-enoate

C22H29O4- (357.2065734)


   

4,5-epoxy-17R-hydroxy-docosahexaenoate

4,5-epoxy-17R-hydroxy-docosahexaenoate

C22H29O4- (357.2065734)


   

7(8)-epoxy-17R-hydroxy-docosahexaenoate

7(8)-epoxy-17R-hydroxy-docosahexaenoate

C22H29O4- (357.2065734)


   

4(5)-epoxy-17S-hydroxy-docosahexaenoate

4(5)-epoxy-17S-hydroxy-docosahexaenoate

C22H29O4- (357.2065734)


   
   

N-[[(1R,2R)-3-Oxo-2-[(Z)-2-pentenyl]cyclopentan-1-yl]acetyl]-L-phenylalanine

N-[[(1R,2R)-3-Oxo-2-[(Z)-2-pentenyl]cyclopentan-1-yl]acetyl]-L-phenylalanine

C21H27NO4 (357.19399820000007)


   
   

N-[[(1R)-3-Oxo-2alpha-[(Z)-2-pentenyl]cyclopentane-1alpha-yl]acetyl]-L-phenylalanine

N-[[(1R)-3-Oxo-2alpha-[(Z)-2-pentenyl]cyclopentane-1alpha-yl]acetyl]-L-phenylalanine

C21H27NO4 (357.19399820000007)


   

(2S)-2-[[2-[3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]-3-phenylpropanoic acid

(2S)-2-[[2-[3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]-3-phenylpropanoic acid

C21H27NO4 (357.19399820000007)


   

delta-9-tetrahydrocannabinolate

delta-9-tetrahydrocannabinolate

C22H29O4- (357.2065734)


   
   

Undec-5-enedioylcarnitine

Undec-5-enedioylcarnitine

C18H31NO6 (357.2151266)


   

Undec-4-enedioylcarnitine

Undec-4-enedioylcarnitine

C18H31NO6 (357.2151266)


   

Undec-3-enedioylcarnitine

Undec-3-enedioylcarnitine

C18H31NO6 (357.2151266)


   

(2E)-Undec-2-enedioylcarnitine

(2E)-Undec-2-enedioylcarnitine

C18H31NO6 (357.2151266)


   

(4E)-3-Hydroxydodec-4-enoylcarnitine

(4E)-3-Hydroxydodec-4-enoylcarnitine

C19H35NO5 (357.25151000000005)


   

(6Z)-3-Hydroxydodec-6-enoylcarnitine

(6Z)-3-Hydroxydodec-6-enoylcarnitine

C19H35NO5 (357.25151000000005)


   

(8Z)-3-Hydroxydodec-8-enoylcarnitine

(8Z)-3-Hydroxydodec-8-enoylcarnitine

C19H35NO5 (357.25151000000005)


   

(7E)-5-Hydroxydodec-7-enoylcarnitine

(7E)-5-Hydroxydodec-7-enoylcarnitine

C19H35NO5 (357.25151000000005)


   

(9E)-7-Hydroxydodec-9-enoylcarnitine

(9E)-7-Hydroxydodec-9-enoylcarnitine

C19H35NO5 (357.25151000000005)


   

(10E)-8-Hydroxydodec-10-enoylcarnitine

(10E)-8-Hydroxydodec-10-enoylcarnitine

C19H35NO5 (357.25151000000005)


   

(2E,10E)-11-(1,3-benzodioxol-5-yl)-N-butan-2-ylundeca-2,10-dienamide

(2E,10E)-11-(1,3-benzodioxol-5-yl)-N-butan-2-ylundeca-2,10-dienamide

C22H31NO3 (357.2303816)


   

Protubonine A

Protubonine A

C19H23N3O4 (357.16884780000004)


An organic heterotetracyclic compound that is 6,10b,11,11a-tetrahydro-H-pyrazino[1,2:1,5]pyrrolo[2,3-b]indole-,4(3H,5aH)-dione substituted by an acetyl group at position 6, a hydroxy group at position 10b and a 2-methylpropyl group at position 3. It has been isolated from in Aspergillus species. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D054659 - Diketopiperazines

   

Pipemidic acid trihydrate

Pipemidic acid trihydrate

C14H23N5O6 (357.1648258)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents

   
   

1-cyclopentyl-1-[(5,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-3-ethylthiourea

1-cyclopentyl-1-[(5,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-3-ethylthiourea

C20H27N3OS (357.18747320000006)


   

(4R,4aS,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol

(4R,4aS,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol

C21H27NO4 (357.19399820000007)


   

(4R,4aS,7S,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol

(4R,4aS,7S,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol

C21H27NO4 (357.19399820000007)


   

N-[2-[[(2S)-3-methyl-1-[[(2S)-3-methyl-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]amino]-2-oxoethyl]carbamic acid tert-butyl ester

N-[2-[[(2S)-3-methyl-1-[[(2S)-3-methyl-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]amino]-2-oxoethyl]carbamic acid tert-butyl ester

C17H31N3O5 (357.2263596)


   

N-[6-(2-amino-4-fluoroanilino)-6-oxohexyl]-4-methylbenzamide

N-[6-(2-amino-4-fluoroanilino)-6-oxohexyl]-4-methylbenzamide

C20H24FN3O2 (357.1852456)


   
   

2-Oxospartein-13-yl 1H-pyrrole-2-carboxylate

2-Oxospartein-13-yl 1H-pyrrole-2-carboxylate

C20H27N3O3 (357.20523120000007)


   

N-[[3-(4-fluorophenyl)-1-phenyl-4-pyrazolyl]methyl]-1-phenylmethanamine

N-[[3-(4-fluorophenyl)-1-phenyl-4-pyrazolyl]methyl]-1-phenylmethanamine

C23H20FN3 (357.1641172)


   

2-(Phenylmethyl)-5-[4-(phenylmethyl)-1-piperidinyl]-4-oxazolecarbonitrile

2-(Phenylmethyl)-5-[4-(phenylmethyl)-1-piperidinyl]-4-oxazolecarbonitrile

C23H23N3O (357.1841028)


   

N-[2-(3-methylphenoxy)ethyl]-5-(4-morpholinyl)-2-nitroaniline

N-[2-(3-methylphenoxy)ethyl]-5-(4-morpholinyl)-2-nitroaniline

C19H23N3O4 (357.16884780000004)


   

6-Amino-2-methyl-8-(4-propan-2-ylphenyl)-1,3,8,8a-tetrahydroisoquinoline-5,5,7-tricarbonitrile

6-Amino-2-methyl-8-(4-propan-2-ylphenyl)-1,3,8,8a-tetrahydroisoquinoline-5,5,7-tricarbonitrile

C22H23N5 (357.1953358)


   

9alpha-Hydroxy-3-oxo-23,24-bisnorchola-1,4-dien-22-oate(1-)

9alpha-Hydroxy-3-oxo-23,24-bisnorchola-1,4-dien-22-oate(1-)

C22H29O4- (357.2065734)


   

3-Hydroxy-9-oxo-9,10-seco-23,24-bisnorchola-1,3,5(10)-trien-22-oate

3-Hydroxy-9-oxo-9,10-seco-23,24-bisnorchola-1,3,5(10)-trien-22-oate

C22H29O4- (357.2065734)


   

N-[2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenyl]acetamide

N-[2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenyl]acetamide

C17H23N7O2 (357.1913138)


   
   
   
   
   
   
   
   
   
   
   
   
   
   

6-Chloro-1-pyrollidino-4-triisopropylsilyloxycyclohexene

6-Chloro-1-pyrollidino-4-triisopropylsilyloxycyclohexene

C19H36ClNOSi (357.22545560000003)


   
   

(1S,2aR,8bR)-4-[cyclobutyl(oxo)methyl]-1-(hydroxymethyl)-N-propyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

(1S,2aR,8bR)-4-[cyclobutyl(oxo)methyl]-1-(hydroxymethyl)-N-propyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

C20H27N3O3 (357.20523120000007)


   

4-[[(1R,5S)-7-[4-[(E)-2-phenylethenyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]methyl]-1,3-oxazole

4-[[(1R,5S)-7-[4-[(E)-2-phenylethenyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]methyl]-1,3-oxazole

C23H23N3O (357.1841028)


   

(1R,2aS,8bS)-4-[cyclobutyl(oxo)methyl]-1-(hydroxymethyl)-N-propyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

(1R,2aS,8bS)-4-[cyclobutyl(oxo)methyl]-1-(hydroxymethyl)-N-propyl-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-2-carboxamide

C20H27N3O3 (357.20523120000007)


   

(2E,4E,6S,8R,10E)-7,9-Dimethoxy-3,6,8-trimethyl-11-phenylundeca-2,4,10-trienamide

(2E,4E,6S,8R,10E)-7,9-Dimethoxy-3,6,8-trimethyl-11-phenylundeca-2,4,10-trienamide

C22H31NO3 (357.2303816)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(2E)-13-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]tridec-2-enoate

(2E)-13-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]tridec-2-enoate

C19H33O6- (357.22770180000003)


   

(E,12R)-12-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxytridec-2-enoate

(E,12R)-12-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxytridec-2-enoate

C19H33O6- (357.22770180000003)


   

N-Acetylvalylleucylalanine methyl ester

N-Acetylvalylleucylalanine methyl ester

C17H31N3O5 (357.2263596)


   

N-Acetyl-valyl-leucyl-alanine methylester

N-Acetyl-valyl-leucyl-alanine methylester

C17H31N3O5 (357.2263596)


   

(S)-Laudanosine

(S)-Laudanosine

C21H27NO4 (357.19399820000007)


D002491 - Central Nervous System Agents

   

e-64

e-64

C15H27N5O5 (357.2012092)


D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents

   

N-Desmethyltamoxifen

N-Desmethyltamoxifen

C25H27NO (357.20925320000003)


C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent

   

(9Z)-3-hydroxydodecenoylcarnitine

(9Z)-3-hydroxydodecenoylcarnitine

C19H35NO5 (357.25151000000005)


An O-acylcarnitine having (9Z)-3-hydroxydodecenoyl as the acyl substituent.

   

oscr#21(1-)

oscr#21(1-)

C19H33O6 (357.22770180000003)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#21, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

ascr#21(1-)

ascr#21(1-)

C19H33O6 (357.22770180000003)


Conjugate base of ascr#21

   
   
   
   
   
   
   
   
   

(1r,2r,3s,5s,7r,8r,12r,13s,18s,21r)-12-methyl-4-methylidene-14,19-dioxa-17-azaheptacyclo[10.7.2.2²,⁵.0²,⁷.0⁸,¹⁸.0⁸,²¹.0¹³,¹⁷]tricosan-3-ol

(1r,2r,3s,5s,7r,8r,12r,13s,18s,21r)-12-methyl-4-methylidene-14,19-dioxa-17-azaheptacyclo[10.7.2.2²,⁵.0²,⁷.0⁸,¹⁸.0⁸,²¹.0¹³,¹⁷]tricosan-3-ol

C22H31NO3 (357.2303816)


   

(1r,2r,5r,7r,8r,9r,10r,13r,16s,17r)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

(1r,2r,5r,7r,8r,9r,10r,13r,16s,17r)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

C22H31NO3 (357.2303816)


   

12-ethyl-7,17-dihydroxy-14-methyl-6-methylidene-12-azahexacyclo[8.7.1.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]nonadecan-4-one

12-ethyl-7,17-dihydroxy-14-methyl-6-methylidene-12-azahexacyclo[8.7.1.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]nonadecan-4-one

C22H31NO3 (357.2303816)


   

(1r,2s,3s,5s,7r,8r,12r,13s,21r)-12-methyl-4-methylidene-14,19-dioxa-17-azaheptacyclo[10.7.2.2²,⁵.0²,⁷.0⁸,¹⁸.0⁸,²¹.0¹³,¹⁷]tricosan-3-ol

(1r,2s,3s,5s,7r,8r,12r,13s,21r)-12-methyl-4-methylidene-14,19-dioxa-17-azaheptacyclo[10.7.2.2²,⁵.0²,⁷.0⁸,¹⁸.0⁸,²¹.0¹³,¹⁷]tricosan-3-ol

C22H31NO3 (357.2303816)


   

(1r,5r,11s,12s,14r,16r,17s,18r,20r,21r)-5-methyl-15-methylidene-10-oxa-7-azaheptacyclo[12.6.2.0¹,¹¹.0⁵,²⁰.0⁷,¹¹.0¹²,¹⁷.0¹⁷,²¹]docosane-16,18-diol

(1r,5r,11s,12s,14r,16r,17s,18r,20r,21r)-5-methyl-15-methylidene-10-oxa-7-azaheptacyclo[12.6.2.0¹,¹¹.0⁵,²⁰.0⁷,¹¹.0¹²,¹⁷.0¹⁷,²¹]docosane-16,18-diol

C22H31NO3 (357.2303816)


   

(1r,3r,4s,5s,8r,9s,11s,14s,17s,18r)-3,4-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione

(1r,3r,4s,5s,8r,9s,11s,14s,17s,18r)-3,4-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione

C21H27NO4 (357.19399820000007)


   

(1r,2r,7r,8s,9r,10r,13r,16s,17r)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

(1r,2r,7r,8s,9r,10r,13r,16s,17r)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

C22H31NO3 (357.2303816)


   

(1s,6s,7s,9r,10s,15r,18s,19r,22s)-9-hydroxy-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

(1s,6s,7s,9r,10s,15r,18s,19r,22s)-9-hydroxy-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one

C22H31NO3 (357.2303816)


   

(1r,3e,5s,10r)-14-hydroxy-3,17,17-trimethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16),14-trien-5-yl acetate

(1r,3e,5s,10r)-14-hydroxy-3,17,17-trimethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16),14-trien-5-yl acetate

C22H31NO3 (357.2303816)


   

n-(1,4-dimethoxy-1,4-dioxobutan-2-yl)-10-methyldodecanimidic acid

n-(1,4-dimethoxy-1,4-dioxobutan-2-yl)-10-methyldodecanimidic acid

C19H35NO5 (357.25151000000005)


   

(6r,7s,10s,15r,16s,18s,19r,22s)-6,18-dimethyl-4-oxo-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-16-ium-16-olate

(6r,7s,10s,15r,16s,18s,19r,22s)-6,18-dimethyl-4-oxo-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-16-ium-16-olate

C22H31NO3 (357.2303816)


   

dimethyl(2-{4,13,14-trimethoxy-2-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-7-yl}ethyl)amine

dimethyl(2-{4,13,14-trimethoxy-2-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-7-yl}ethyl)amine

C21H27NO4 (357.19399820000007)


   

(1r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline

(1r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline

C21H27NO4 (357.19399820000007)


   

5-hydroxy-4-(1-hydroxy-2,4-dimethyloct-6-en-1-ylidene)-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

5-hydroxy-4-(1-hydroxy-2,4-dimethyloct-6-en-1-ylidene)-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

C21H27NO4 (357.19399820000007)


   

(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-5-({[(2r,3s)-3-[(2s)-butan-2-yl]-4-oxooxetan-2-yl](hydroxy)methylidene}amino)pentanoic acid

(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-5-({[(2r,3s)-3-[(2s)-butan-2-yl]-4-oxooxetan-2-yl](hydroxy)methylidene}amino)pentanoic acid

C16H27N3O6 (357.1899762)


   

(4e)-5-hydroxy-4-[(6e)-1-hydroxy-2,4-dimethyloct-6-en-1-ylidene]-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

(4e)-5-hydroxy-4-[(6e)-1-hydroxy-2,4-dimethyloct-6-en-1-ylidene]-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one

C21H27NO4 (357.19399820000007)


   

n-[(2r)-1,4-dimethoxy-1,4-dioxobutan-2-yl]-10-methyldodecanimidic acid

n-[(2r)-1,4-dimethoxy-1,4-dioxobutan-2-yl]-10-methyldodecanimidic acid

C19H35NO5 (357.25151000000005)


   

(1r,2s,5r,7r,8r,9r,10s,13r,16s,17r)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

(1r,2s,5r,7r,8r,9r,10s,13r,16s,17r)-11-ethyl-7,16-dihydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

C22H31NO3 (357.2303816)